These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 16919011)

  • 1. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases.
    Cozzi F; Montisci R; Marotta H; Bobbo F; Durigon N; Ruscazio M; Sfriso P; Iliceto S; Todesco S
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():49-53. PubMed ID: 16919011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP; Humbert M; Rubin L; Black CM
    Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
    Ahmadi-Simab K; Hellmich B; Gross WL
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
    Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Two-years therapy with bosentan of pulmonary arterial hypertension related to connective tissue diseases].
    Marotta H; Montisci R; Tiso F; Pontarollo S; Rizzo M; Tona F; Iliceto S; Cozzi F
    Reumatismo; 2007; 59(4):299-303. PubMed ID: 18157286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pulmonary arterial hypertension in connective tissue disease].
    Cottin V
    Rev Mal Respir; 2006 Sep; 23(4 Suppl):13S61-72. PubMed ID: 17057632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of bosentan on the skin lesions: an observational study from a single center in Japan.
    Funauchi M; Kishimoto K; Shimazu H; Nagare Y; Hino S; Yano T; Kinoshita K
    Rheumatol Int; 2009 May; 29(7):769-75. PubMed ID: 19037604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
    Sitbon O; Beghetti M; Petit J; Iserin L; Humbert M; Gressin V; Simonneau G
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
    Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
    Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S
    Heart; 2005 Nov; 91(11):1447-52. PubMed ID: 15761050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases.
    Cella G; Vianello F; Cozzi F; Marotta H; Tona F; Saggiorato G; Iqbal O; Fareed J
    J Rheumatol; 2009 Apr; 36(4):760-7. PubMed ID: 19208592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study.
    Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S
    Heart; 2007 Mar; 93(3):350-4. PubMed ID: 16980516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
    Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
    Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
    McLaughlin VV
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.
    Oudiz RJ; Schilz RJ; Barst RJ; Galié N; Rich S; Rubin LJ; Simonneau G;
    Chest; 2004 Aug; 126(2):420-7. PubMed ID: 15302727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease.
    Benza RL; Rayburn BK; Tallaj JA; Coffey CS; Pinderski LJ; Pamoukian SV; Bourge RC
    Chest; 2006 Apr; 129(4):1009-15. PubMed ID: 16608951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension.
    Mok MY; Tsang PL; Lam YM; Lo Y; Wong WS; Lau CS
    Lupus; 2007; 16(4):279-85. PubMed ID: 17439935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension.
    Degano B; Yaïci A; Le Pavec J; Savale L; Jaïs X; Camara B; Humbert M; Simonneau G; Sitbon O
    Eur Respir J; 2009 Jan; 33(1):92-8. PubMed ID: 18799506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?
    van Loon RL; Hoendermis ES; Duffels MG; Vonk-Noordegraaf A; Mulder BJ; Hillege HL; Berger RM
    Am Heart J; 2007 Oct; 154(4):776-82. PubMed ID: 17893008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.